Engineered virus targets and kills apparent cancer stem cells in neuroblastoma

January 21, 2009

Treatment blocked deadly nerve cancer in study led by Cincinnati Children's

CINCINNATI - After identifying an apparent population of cancer stem cells for neuroblastoma, researchers successfully used a reprogrammed herpes virus to block tumor formation in mice by targeting and killing the cells.

Published online Jan. 21 by PLoS (Public Library of Science) One, the study led by Cincinnati Children's Hospital Medical Center adds to a growing body of evidence suggesting early stage cancer precursor cells with stem-cell-like properties may explain how some cancers form, are treatment resistant and prone to relapse. The study also underscores the increasing potential of targeted biological therapies to help people with stubborn cancers like neuroblastoma, which often recur and metastasize, said Timothy Cripe, M.D., Ph.D., senior investigator and a physician/researcher in the division of Hematology/Oncology at Cincinnati Children's.

"The main finding of our study is that pediatric neuroblastomas seem to have a population of cells with stem-cell characteristics that we may need to target for therapy," Dr. Cripe said. "We also show that one promising approach for targeted treatment is biological therapy, such as an engineered oncolytic virus that seeks out and kills progenitor cells that could be the seeds of cancers."

Neuroblastoma's solid tumors usually attack the sympathetic nervous system, part of the body's autopilot mechanism that controls vital organ function and instinctive responses, like "fight or flight." The disease can be thrown into remission by chemotherapy, radiation or surgery, but it's also known for treatment resistance and a high rate of relapse and death. In patients with high-risk forms of the disease, long-term survival rates are less than 50 percent. The reasons for neuroblastoma's tendency to relapse and spread still need to be proven, said Dr. Cripe, also professor of Pediatrics at the University of Cincinnati College of Medicine.

To further explore the cancer stem cell theory, the research team took human neuroblastoma cells and grew them in laboratory cultures. The cultures contained cells exhibiting biological properties of neural stem cells - which are specific to the nervous system and grow to form a variety of nerve tissue. The cultures generated cell colonies that acted like stem cells in the way they divided, grew and were capable of diverse, or multi-lineage, differentiation. Analysis showed the cells also carried known biological markers for nerve stem cells, such as the proteins CD133 and nestin.

The cells advanced into tumor-like cell spheres and were tumorigenic, meaning they had the potential to form tumors. Cells derived from these tumorspheres were relatively resistant to the chemotherapy agent doxorubicin, similar to that seen with some treatment-resistant neuroblastomas. Researchers also noted cells from the tumorspheres carried a gene (MYCN) that is found at amplified levels in aggressive forms of neuroblastoma.

Because neural stem cells and neuroblastoma cells both carry the protein nestin, Dr. Cripe and his colleagues tested the effect of an oncolytic herpes simplex virus called rQNestin34.5 on cells. Developed by cancer researchers Ohio State University, rQNestin34.5 carries a molecular promoter for nestin, which causes it to seek out the protein and cancerous, or precancerous, cells where nestin resides. The virus is genetically programmed to grow inside and be toxic to cancer cells, while leaving healthy tissues alone.

The tumorigenic cells were infected with rQNestin34.5 and then injected into mice to see if neuroblastoma tumors would form. Tumors did not form in any of the mice over a 60-day observation period, leading the researchers to report that rQNestin34.5 "abolished tumor growth" by attacking apparent tumor-initiating cells.

In comparison experiments for control, researchers also infected tumorigenic cells with another oncolytic herpes virus called rQLuc, which does not target cells that contain the nestin protein. Next to rQNestin34.5, rQLuc showed only moderate success, with all treated mice having tumor formation within 40 days. In mice where cells were treated only with saline, all animals had tumors form within 30 days.

Although a promising step forward, Dr. Cripe said the study's main limitation is that precancerous cells were infected with the oncolytic virus in a laboratory culture before being injected into mice.

"Targeting and hitting the cells after they are already in the mice will be another matter," he said.

The research team also nurtured the stem-cell like tumorigenic cultures over an extended period of time in the laboratory. In the next research phase, the team will try to verify results in the current study by seeing if they can detect the presence of cancer stem cells in primary neuroblastoma tumor cells from patients.

Dr. Cripe cautioned much more research is needed before determining whether rQNestin34.5 would be efficacious in treating neuroblastoma patients in a clinical setting.

Cincinnati Children's Hospital Medical Center

Neuroblastoma
by Nai-Kong V. Cheung (Editor), Susan L. Cohn (Editor)

Neuroblastoma is a medical enigma. As a childhood neoplasm arising from neural crest cells, it is characterized by diverse clinical behaviors ranging from spontaneous remission to rapid tumor progression and death. Although clinical outcome can be predicted to a large extent by the stage of disease and the age at diagnosis, an in-depth understanding of its clinico-pathological behavior, now greatly aided by sophisticated molecular genetic profiling, will improve diagnostic precision and refine risk-based therapies. Comprehensive international efforts have advanced our understanding of tumor biology and improved the clinical management of children with neuroblastoma. This book reviews our current understanding of the genes and biological pathways that contribute to neuroblastoma...

Neuroblastoma (Pediatric Cancer: Diagnosis, Therapy, and Prognosis, Vol. 1)
by M.A. Hayat (Editor)

Introduction of new technologies and their applications to neuroblastoma diagnosis, treatment, and therapy assessment are explained. Role of molecular ghenetics in diagnosis and therapy for neuroblastoma patients is detailed. Molecular detection of minimal residual neuroblastoma is described. Magnetic resonance imaging and spectroscopy are detailed for diagnosing this solid, extracranial cancer. Targets for therapeutic intervention in neuroblastoma are identified, including targeting multidrug resistance in this cancer. Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. The effectiveness of chemotherapy with oral irinotecan and temozolomide is explained. The role of transcription factors (GATA) in neuroblastoma pregression is also included.

Olfactory neuroblastoma.(PATHOLOGY CLINIC)(Disease/Disorder overview): An article from: Ear, Nose and Throat Journal
by Lester D.R. Thompson (Author)

This digital document is an article from Ear, Nose and Throat Journal, published by Thomson Gale on September 1, 2006. The length of the article is 798 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Olfactory neuroblastoma.(PATHOLOGY CLINIC)(Disease/Disorder overview)
Author: Lester D.R. Thompson
Publication: Ear, Nose and Throat Journal (Magazine/Journal)
Date: September 1, 2006
Publisher: Thomson Gale
Volume: 85 Issue: 9 Page: 569(2)

Article Type: Disease/Disorder overview

Distributed by Thomson...

Advances Neuroblastoma Res (Progress in cancer research and therapy)
by Evans (Author)

The Official Parent's Sourcebook on Neuroblastoma: A Revised and Updated Directory for the Internet Age
by Icon Health Publications (Author)

This sourcebook has been created for parents who have decided to make education and Internet-based research an integral part of the treatment process. Although it gives information useful to doctors, caregivers and other health professionals, it also tells parents where and how to look for information covering virtually all topics related to neuroblastoma, from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on neuroblastoma. Following an introductory chapter, the sourcebook is organized into three...

The Neurology of Neuroblastoma: Neuroblastoma as a Neurobiological Disease
by Nina Felice Schor (Author)

Neuroblastoma is the single most common solid tumor of childhood. Although children with small primary neuroblastomas alone are almost always cured by surgery, 65% of children with neuroblastoma already have large bulky tumors or metastatic disease by the time of initial diagnosis. For these children, the 5-year survival rate is only somewhere between 5% and 20% with therapies including surgery, radiation, chemotherapy, and bone marrow transplantation. Dr Schor outlines a new approach to these tumors in order to make a difference for these children. There is much information to support the notion that neuroblastomas represent a developmental aberration of the nervous system, rather than a de novo abnormality in a previously normal cell. While the remote, paraneoplastic effects of...

Advances in neuroblastoma research: Proceedings of the Third Symposium on Advances in Neuroblastoma Research held in the Children's Hospital of ... in clinical and biological research)
by Liss (Publisher)

The Epidemiology of Neuroblastoma
by Stefano Parodi (Author), Riccardo Haupt (Author)

Neuroblastoma is a cancer of the sympathetic nervous system. It is the most common tumor in the first year of life and the most common solid extra-cranial cancer in childhood. Neuroblastoma represents an enigmatic disease, in that some cases, especially in infants, tend to spontaneously regress, even in advanced states, while many patients are refractary to any therapeutical approach and show an inexorable clinical course. As most of the other solid cancers in children, the distribution of Neuroblastoma risk worldwide is only partly known. In Western countries, its incidence varies between 7 and 16 cases per million children and it tends to decrease increasing the age.Besides, survival of patients affected by such disease, in relation with clinical and biological characteristics, have...

Cancer in the First Year of Life: Leukemias, Neuroblastomas, Soft Tissue Sarcomas (Contributions to Oncology)
by Germany) Italo-German Workshop on Pediatric Oncology 1989 (Braunfels (Author), L. Cordero Di Montezemolo (Author), A. Pession (Author), Fritz Lampert (Author), Fritz Lampert (Contributor)

Neuroblastomas: Webster's Timeline History, 1949 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Neuroblastomas," including when used in literature (e.g. all authors that might have Neuroblastomas in their name). As such, this book represents the largest compilation of timeline events associated with Neuroblastomas when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts,...